Objective: To investigate the therapeutic effect and primary pharmacological mechanism of Ziyuglycoside I (Ziyu I) on collagen-induced arthritis (CIA) mice. Methods: CIA mice were treated by 5, 10, or 20 mg/kg of Ziyu I or 2 mg/kg of methotrexate (MTX), and clinical manifestations as well as pathological changes were observed. T cell subsets were determined by flow cytometry. T cell viability was measured by CCK-8. The expressions of transforming growth factor beta (TGF-β) and IL-17 in serum were detected by Elisa. The mRNA expressions of RORγt and Foxp3 in mice spleen lymphocytes were detected by RT-qPCR. Molecular docking was used to detect whether there was a molecular interaction between Ziyu I and Akt. The activation of mTOR in T cells was verified by Western blotting or immunofluorescence. Results: Ziyu I treatment group could effectively alleviate the arthritis symptoms of CIA mice, including body weight, global score, arthritis index, number of swollen joints, etc. The pathological changes of joints and spleen in arthritic mice were improved effectively. The thymic index, T cell activity and RORγt production of Ziyu I treatment group were significantly reduced. Notably, through molecular docking, western blotting, and immunofluorescence analysis data, we found that Ziyu I could interact directly with Akt to reduce downstream mTOR activation and inhibit Th17 differentiation, thereby regulating Th17/Treg balance and improving arthritis symptoms. Conclusion: Our data showed that Ziyu I effectively improved arthritic symptoms of CIA in mice by inhibiting mTOR activation, thereby affecting Th17 differentiation and regulating Th17/Treg balance.